US 11,298,414 B2 · Cellular adjuvants for viral infection

Abstract

Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

Claims8

Dependent claims

A method of increasing expression of a recombinant antigen in a dendritic host cell, comprising:

providing an adenovirus having a genome that includes a recombinant sequence encoding an antigen, wherein the sequence is operably linked to a promoter to drive expression of the antigen in the dendritic host cell;
providing a non-host cell selected from a group consisting of Escherichia coli and Saccharomyces cerevisiae;
and
concurrently exposing the dendritic host cell with both the adenovirus and the non-host cell under conditions to allow uptake of the virus into the host cell and to allow for expression of the recombinant sequence in the host cell;
and wherein the exposure of the dendritic host cell with the non-host cell is in an amount that increases expression of the antigen.

2 more elements

Dependencies are inferred from the claim text.

Cellular adjuvants for viral infection

Life of this patent

Cellular adjuvants for viral infection

Life of this patent

Abstract

Claims8